[1]
F. Petrelli, A. Caraffa, S. Scuri, I. Grappasonni, E. Magrini, and A. Cocchini, “The requirements for manufacturing highly active or sensitising drugs comparing Good Manufacturing Practices”,
Acta Biomed, vol. 90, no. 2, pp. 288–299, May 2019, doi:
10.23750/abm.v90i2.8340.